The estimated Net Worth of Jeffrey Brian Mc Groarty is at least $275 mil dollars as of 30 October 2017. Jeffrey Groarty owns over 875 units of Annovis Bio stock worth over $274,543 and over the last 12 years Jeffrey sold ANVS stock worth over $0.
Sign up
Jeffrey Groarty ANVS stock SEC Form 4 insiders trading
Jeffrey has made over 5 trades of the Annovis Bio stock since 2013, according to the Form 4 filled with the SEC. Most recently Jeffrey exercised 875 units of ANVS stock worth $8,601 on 30 October 2017.
The largest trade Jeffrey's ever made was exercising 16,666 units of Annovis Bio stock on 5 December 2013 worth over $200,992. On average, Jeffrey trades about 539 units every 22 days since 2012. As of 30 October 2017 Jeffrey still owns at least 31,998 units of Annovis Bio stock.
You can see the complete history of Jeffrey Groarty stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jeffrey Groarty's mailing address?
Jeffrey's mailing address filed with the SEC is C/O ANNOVIS BIO, INC., 1055 WESTLAKES DRIVE, SUITE 300, BERWYN, PA, 19312.
Insiders trading at Annovis Bio
Over the last 5 years, insiders at Annovis Bio have traded over $0 worth of Annovis Bio stock and bought 24,481 units worth $662,591 . The most active insiders traders include Michael B Hoffman, Maria Luisa Maccecchini, eJeffrey Brian Mc Groarty. On average, Annovis Bio executives and independent directors trade stock every 138 days with the average trade being worth of $158,018. The most recent stock trade was executed by Maria Luisa Maccecchini on 6 February 2023, trading 52,755 units of ANVS stock currently worth $7,386.
What does Annovis Bio do?
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
What does Annovis Bio's logo look like?
Complete history of Jeffrey Groarty stock trades at Safeguard Scientifics e Annovis Bio
Annovis Bio executives and stock owners
Annovis Bio executives and other stock owners filed with the SEC include:
-
Mark White,
Board Member -
Robert Whelan,
Board Member -
Claudine Bruck,
Board Member -
Maria Maccecchini,
Executive Board Member -
Michael Hoffman,
Chairman of the Board -
Reid Mc Carthy,
Director -
Jeffrey Brian Mc Groarty,
Chief Financial Officer -
Henry Iii Hagopian,
Chief Financial Officer